Q1 2020 Earnings Call
Ladies and gentlemen, thank you for standing by welcome to the first quarter 2020, West Pharmaceutical services earnings Conference call.
This time all participants are in listen only mode. After the speaker presentation. There will be a question and answer session to ask a question. During the session you will need to press star one on your telephone.
Please be advised the todays conference is being recorded if your acquire any further assistance. Please press star zero.
It is now my pleasure to introduce vice President of Investor Relations Quintin Lai.
Thank you Andrew.
Good morning, and welcome to Whats first quarter 2020 conference call.
We issued our financial results. This morning, and the release has been posted on the Investor section on the company's website located at once pharma Dot com.
This morning, CEO, Eric Green and CFO, Bernard Birkett will review our results.
I didn't update on our business and present, our updated financial outlook for the full year 2020.
There is a slide presentation that accompanies todays call and a copy of that presentation is available on the investor section of our website.
On slide two is our safe Harbor statement.
That's made by management on this call and in the accompanying presentation contain forward looking statements within the meaning of U.S. Federal Securities law.
These statements are based on our beliefs and assumptions current expectations estimates and forecast.
The company's future results are influenced by many factors beyond the control the company and actual results could differ materially from past results as well as those expressed or implied in any forward looking statement made here.
Please refer to todays press release as well as any other disclosures made by the company regarding the risk to would you. There's some good including our 10-K 10-Q, an 8-K reports.
During today's call management will make reference to non-GAAP financial measures, including organic sales growth adjusted operating profit.
Adjusted operating profit margin, an adjusted diluted EPS.
Conciliations and limitations of the non-GAAP financial measures to the most comparable financial results prepared in conformity the gap.
Our provided in this morning's earnings release.
I'd now turn the call over to West CEO, and President and great there.
Thank you Clinton and good morning, everyone. Thank you for joining us today.
Past several months have been some of the most difficult times for our communities across the world.
As we faced challenging circumstances related to cobot 19.
This pandemic had made clear the importance of global health care and the criticality of the role West plays during these unprecedented times.
Our mission to improve patient lives cannot be any more meaningful then in times like today.
We take great pride that for nearly 100 years, we have provided innovative.
Quality products and solutions for the containment and delivery of injectable medicines.
Despite the cold in 18 challenges the west team remains focused on creating and delivering value to all our stakeholders.
What's that two priorities there in guiding us through this pandemic.
First and foremost we're focused on the wellbeing and safety of our team members across the globe.
Our crisis management team was engaged at the outset implemented precautionary measures across our company to protect our teams.
It seems near nearly every day I learned about another great way that our team is stepping up to deliver the critical components to meet the urgent needs of our customers and their patients while looking out for the safety a one another.
These moments are not only inspirational, but they serve as a testament to the collective strength of the one whats team and I'm grateful for their unwavering commitment to our mission.
In addition, our culture of philanthropy and community involvement has our team members operating their time reading skills and knowledge in support of local response efforts.
Turning to slide four.
Our second priority is the continuity a manufacturing and supply of components of solutions to our customers.
The strong tenant Submarket led strategy and globalization of the manufacturing network are contributing to the resiliency of whats business and today's climate.
I'm pleased to say that the growth trends, we experienced throughout 2019 have continued in the first quarter and the outlook for the balance of the year remains positive.
Despite the current challenges so far we have been able to maintain operations and normal capacity.
For the benefit of our customers.
Have been able to leverage our world class Global manufacturing network by enabling the right capabilities scale and flexibility to keep up the increase in demand.
Because of the constantly changing environment and its effect on the economy, we conduct business impact and elsie's daily and make adjustments as they are required.
These assessments are an integral part of her business continuity plans within each of our global sites in operation that work.
Throughout the past several months, we've monitored our supply chain, including our close partner Daikyo and at this time do not foresee any negative impact from direct or indirect suppliers.
As a pandemic has intensified as expected we have seen an increase in customer orders in recent weeks, we are monitoring order flow to ensure that we're addressing the true demand for our products.
As shown on slide five despite today's uncertain environment I am pleased to report that we had a strong first quarter performance and we entered the second quarter well position.
We had 13% organic sales growth in the first quarter largely through strong high value product sales.
This resulted in double digit growth in adjusted EPS for the first quarter.
As we enter the second quarter.
The demand for products continues to be solid.
From both existing customers as well as new opportunities from companies looking to develop cobot 19 solutions.
Each day seems to bring new challenges supply chain transportation government regulations, and I want to emphasize that across west were operating with a sense of urgency to address and manage these issues.
Now I'll turn it over to our CFO burner for Cat, who will provide more detail on our first quarter financial performance burner.
Thank you, Eric and good morning I.
I hope everyone. Its LT unsafe during this time.
Well, let's review the numbers in more detail.
First look at Q1, 2020 revenues and profits, where we saw strong sales and EPS growth.
By strong revenue performance, primarily in our biologics and generics market units and contract manufacturing.
I will take you through the margin growth, we saw in the quarter as well as some balance sheet takeaways.
And finally, we will review guidance for 2020.
First off Q1.
Our financial results are summarized on slide six and the reconciliation of non U.S. GAAP measures are described in slide 13 to 16.
We recorded net sales of $491.5 million, representing organic sales growth of 12.7% and 30 basis points of inorganic growth.
Proprietary products sales grew organically by 11.8% in the quarter.
High value products, which make up more than 63% of proprietary product sales grew double digits and had solid momentum across all market units throughout Q1.
Looking at the performance of the market unit.
Biologics market unit delivered strong double digit growth, we continue to work with many biotech and biopharma customers, who are using west and die keel high value product offerings.
The generics market units experienced high single digit growth led by sales.
Weststar and flora Tech components.
Our pharma market Eunice so mid single digit growth with sales led by high value products and services, including West are no, but pure him for a check components.
And the contract manufacturing had double digit organic sales growth for the first quarter led once again by sales of diagnostic and healthcare related injection system.
Moving to slide seven we continue to see improvements in gross profits, we recorded $167 million and gross profit 20 million or 13.6% above Q1 of last year.
Gross profit margin of 34% was a 90 basis point expansion from the same period last year.
We saw improvement in adjusted operating profit with $88 million reported this quarter compared to 71.3 million in the same period last year.
23.4% increase.
Our adjusted operating profit margin of 17.9% was a 180 basis point increase from the same period last year.
And finally, adjusted diluted EPS grew 36% for Q1.
Excluding stock tax benefit EPS grew by approximately 31%.
So what's driving the growth in both revenue and profit.
On slide eight we show the contributions to sales growth in the quarter volume and mix contributed $51.1 million or 11.5 percentage points of growth.
Those price increases contribution to $6.6 million, a 1.5 percentage points of growth.
And changes in foreign currency exchange rates reduced sales by $9.7 million.
A reduction of 2.2 percentage points.
Looking up margin performance slide nine shows our consolidated gross profit margin of 34% for Q1 2020 up from 33.1% in Q1 2019.
Proprietary products first quarter gross profit margin of 40.2% was a 130 basis points above the margin achieved in the first quarter of 2019.
The key drivers of the continued improvements in proprietary product.
Gross profit margin were favorable mix of products sold driven by growth in high value products.
Production efficiencies and sales price increases, partially offset by increased overhead costs.
Contract manufacturing first quarter gross profit margin of 14.3% was 30 basis points above the margin achieved in the first quarter of 2019.
Our adjusted operating profit margin of 17.9% what's.
180 basis point increase from the same period last year.
Actually attributable to our proprietary products gross profit expansion.
Now, let's look at our balance sheet and review, how we've done in terms of generating more cash for the business.
Slide 10, we have led to some key cash flow metric.
Operating cash flow was $57.1 million for the first quarter 2020.
An increase of 9.5 million compared to the same period last year at 20% increase.
Our Q1 2020 capital spending was $32.1 million 3.3 million higher than the same period last year and in line with guidance.
Working capital of 633.1 billion at March 31, 2020 was 74 million lower than at December 31, 2019, primarily due to a reduction in our cash and cash equivalents.
Our cash balance at March 31 of $335.3 million was 103.8 million less than our December 2019 balance primarily due to a 150 million.
Dollars of expenditures under our share repurchase program.
Our capital and financial resources, including overall liquidity remains strong.
Turning to guidance.
Slide 11 provides a high level summary.
Full year 2020, net sales guidance continues to be in a range of between 1.95 billion.
$1.97 billion.
This includes an estimated headwind or $26 million based on current foreign exchange rates.
Compared to prior guidance, which forecasted a 15 million dollar headwind.
We expect organic sales growth looks to be approximately 8%.
We expect our full year 2020 reported diluted EPS guidance.
To be in a range of $3 52 to $3 62 compared to prior guidance of $3 45 to $3 55.
Capital expenditure will be in a range of $130 million to $140 million.
There are some key elements I want to bring your attention too as you review our guidance.
Estimated FX headwind on EPS has an impact of approximately seven cents.
Based on current foreign currency exchange rates compared to prior guidance for saying.
The revised guidance also includes a seven cents EPS impact from our first quarter tax benefits from stock based compensation.
So to summarize the key takeaways for the first quarter.
Strong topline growth in both proprietary and contract manufacturing.
Gross profit margin improvement growth in operating profit margin growth in adjusted diluted EPS growth in operating and free cash flow.
Our sales and EPS projections for 2020 and performance are inline with our long term constructs of approximately 6% to 8% organic sales growth and EPS expansion.
I'd now like to turn the call back over to Eric.
Thank you burner.
Our company is financially strong today more than ever the pursuit of our mission is priority in that taken for granted.
What's products are needed by patients across the globe and in many cases, where the administration of lifesaving medicines.
As the market leader, we are committed to ensure continuity of supply to our customers around the globe.
In addition, we are supporting our many customers that are development potential solutions to address cobot 19 with components for diagnostics anti viral therapeutics and vaccines.
We are confident in our long term growth strategy.
Although these are trying times, we are oxton optimistic and dedicated to doing what is necessary supporting the healthcare industry as it works to resolve this global pandemic.
We will emerge from this experience collectively stronger.
And on behalf of all the team members at West. It is our wish that you stay healthy and safe and the days ahead.
Andrew we're ready to take questions. Thank you.
Ladies and gentlemen, as a reminder to ask a question you will need to press star one on your telephone.
To withdraw your question press the pound key please standby, while we compile the culinary roster.
And our first question comes from the line of Larry Solow CJS Securities.
Good morning, guys. Thanks for taking my questions and congrats on a good quarter could start.
Great. Thank you Larry.
On the proprietary sales.
Sean outside of that obviously very good growth.
Coming from that the usual suspects here I'm, not particularly impressed with the margins on the gross side, a 130 bips up year over year and yes I think.
Last year Q1 was also a very good quarter. So on a full year basis. It was up over 150 Bips.
I'm not asking will these trends continue but just what if you peel back the on in a little bit.
It seems like obviously mix is driving a lot of that and that just mix within mix as you did not only increase your high value products percentage, but.
Maybe go off the scale within high value products to more of like set an overview and stuff like that and give us a little more color on that.
Yes, Larry.
Good morning. Thank you for the question, it's good to hear you or your voice.
You're absolutely correct. There is what's happening with proprietary is really two leavers are being pulled simultaneously.
One is the high value product mix.
Effect, but more importantly is that we're seeing increased growth and contribution of that growth with the products that have even higher margins, we started thinking about nova here.
Daikyo Crystal Crystal Zenith.
Even the floral tech.
When you look at those in totality, that's roughly let's say about half the incremental growth.
When it comes to the the high value products and and with a much higher margin. So the mix shift is occurring through high value products, but even more pronounced.
The higher margin sub sets of that portfolio. The second lever that we are only to the tune sooner really good job is globalization of our operations in the as you know we've been on this journey for a couple years now and the team has done a phenomenal job start.
Many lean process season initiatives across our plans, which is allowing us to be more efficient the more effective and higher throughput. So the combination of both of them are giving us that type of margin expansion and proprietary and what excites me is we think about the future pipeline is around the noble.
Here the floor attack the CZ, the self injection portfolio and that that's what that that's what's really exciting as we think about the long term growth trajectory this business.
Okay, Great and then just switching gears I just met coal that 19, just sort of a couple of questions. There how do you gauge sort of.
Surge in orders.
Versus sort of true demand then timing impact then.
Yes.
The.
The to gear up in diagnostics and potential vaccines and therapies is that even that moving the needle for you guys and their short Ron and then lastly on the call that with a drop in oil.
Significant drop in oil realize there'll be some lag effect to that but I would assume that would benefit you guys on.
As we look out of the next few quarters. Thanks, Yeah, Larry in the Covidien team that specifically around our sales and products being introduced to support and I mentioned three areas around diagnostics therapeutics and also vaccines.
In Q1, we did not see any incremental revenue as a company.
Due to over 19, we had some that frankly Bernard can get a little more detail, but we did we did have some additional costs.
But what we're seeing right now then with the approach we've taken with this but the market units were able to have much more granular discussions.
With our customers as we start thinking about Q2 in Q3, we are actively working in all three corridors to give you. An example in the diagnostics our contract manufacturing arm of the business is currently scaling up on consumable products are used in a couple of the.
Devices that are been introduced in the market recently.
We won't speak about specific customer, but these have been introduced recently into the hospitals in the clinic setting.
When it comes to therapeutics. There are a few that are in a market that we're already.
Supporting and been commercialize, but Theyre look there currently as you know going through clinical tests to see the ability to combat cobot 19 and were in those areas and the lastly, the vaccines and those a little more long term as we look out.
2021.
And our floor Tech technology is perfect candidate.
For the back end markets. So it's kind of a staged approach and we'll see some of the benefit in 2020.
And but most of it will be in 2021, you want to bring to talk about the oil.
Yes. So they there are some there'll be a tailwind from oil, but the results and some headwind that we won't see to offset that so, particularly around the logistics side on race.
I've seen some increased costs, there given the well documented and.
Issues with getting products to customers and just the supply chain itself and the impact over the is having on that and then we have all we welcome to some other costs that were absorbing and in supporting our employees as as we're managing through a pandemic. We saw some of it in Q1 and there was some.
It primarily showed up in RCM goals margin, which was of the impact of most bite asked.
But I think.
Well again, we'll see some benefit but there are other headwinds and offsets there.
Got it okay, great. Thank you guys appreciate it.
Color.
Thank you.
And our next question comes from the line of Paul Knight with Janney.
Hi, Eric could you talk about.
What you need to do to minimize risk Uber facility shutdown I know you're operating in a effectively a clean room operation in many sites but.
You have to go another step higher do you do alternate shifts what do you do too.
Redo your risk for the facility.
Thank you Paul and good morning, no you're absolutely correct, we took a very proactive approach.
Months ago, when we started the.
What we learn from our colleagues in Asia, particularly in our.
Billion China.
Also in South and Singapore.
What we've done is that we've taken a.
Multiple steps that we've taken one is let's shift.
To minimize.
They didn't ship Andover minimize interaction and pull that most of this very important.
Also as Im sure monitoring we also put.
At program in place that only essential employees were allowed to go into facilities. So you can imagine at our plants on the 25 plants around the world we have.
Very important.
Goals, but these are individuals that actually work.
Remotely and we put that in place immediately one other element we put in place we really focused on ensuring that when when our colleagues are not feeling well, Oregon. One question about recall that they don't feel pressure to come into the office. So we relax some of our.
Attendance policies.
We expanded our compensation is somebody had to stay at home for a period of time will cover taking care of themselves and or their family members. So those are many different levers that we put in place.
And ensure that people are in the plan should be in the plants.
And also mitigating any.
Any risks that we have from may be coming from the outside.
Prices management team, we put in place is monitoring daily we can tell you.
India is absenteeism issues in the bigger slate.
I'm very pleased actually humble.
And how well the the absent even very low.
Then ballpark multiple sites and I know in Europe. They went up slightly but it came back down to normal rates in the last several weeks, which in general estimate.
Our employees really understand the purpose of why we're doing this and as importantly unity.
So there's a lot of levers that we all all is not just one solution many.
And we're not going to let off on the intensity of this.
Of our approach is we cannot afford to have an issue.
Yeah.
And lastly regarding.
Could you tell if there was talking going on in the industry in Q1.
Yes, Paul we do not see stocking they'll tell you why youre business through walls that were really make to order. So in November and December is really the time period of when we look at Q1.
Demand that we need to manufacture over the following three to four months I will tell you. This though not recent weeks the conversations have intensified where customers are coming to us and thats where our.
Our commercial organization has done a great job.
Categorizing and working with customers to alleviate their concern not to do increase in safety stock because our lead times have not increase because of the global network that we put in place than we were able to categorize any incremental revenues is a due to vaccines therapeutics supporting therapy.
These hospital in the enablement.
And also frankly.
Chris and safety stocks and that's what we're keeping an eye on at this point in time that hasn't as had been as pronounced we've learned our lesson back in 2015 in 2016, and so we're very conscious of that.
And we have the right programs in place to monitor and manage through this.
Thank you.
Thank you.
Next question comes from the line of David Windley with Jefferies.
Hi, Good morning. This is Dan lay on for Dave Thanks for taking your questions.
I think you mentioned and proprietary products that youre mix is improving toward higher margin.
HBP and I wanted to hone in on noble if you're a little bit can you give us a sense of how large that is as a percentage of proprietary products and what the growth is and then is the growth being driven by existing products or an expansion of the product portfolio in that line.
They this is twofold one is six it's expanding the novo.
Sure are nowhere brand portfolio.
With additional products and capabilities.
But it is if you think about novo Nova peer is actually close to a double.
On an absolute dollar value.
During the during the quarter and that's that's a trend that we're currently seeing that started back in late 2018 2018.
Give me an example, one new product portfolio that we launched within though appears a one of the three ml.
Which we believe funds your which we believe can.
Continued to help have this growth rate.
Continue and we have a very high participation rate on and Deejays.
So very very positive.
Portfolio and but there's lot of runway ahead of us in that area.
We've also seen growth and other high value products sold.
C C Lora tech or you self injection system, so we've seen growth.
Strong growth in all of those areas and through Q1, and it's represented in many of them in the various markets units, it's not just in one market units.
Great Thanks to the detail.
I had maybe a follow up question.
The company had a really strong first quarter, but.
Revenue guidance was reaffirmed and so I was wondering if you could give us some of the puts and takes of that guidance.
In the context of how strong Q1 was.
Yes, I Wonder I will let me start and then Bernard will will talk more about the puts and takes I.
I just wanted to caution I mean.
Absolutely. We think you look at the resiliency the business and how the team is executing well under these circumstances and I do truly believe.
The tenants that we put in place from the market led the globalization the operations Digitization, which is allowing us to be a better analytics and real time information, it's really allowing us to drive growth and we saw that.
Some of the growth in Q1, we saw that in a.
Q4 last year and so we believe its continuation, but frankly speaking the operating environment that everybody is is in today is difficult and so.
We want to be my point of view want to be prudent stick with what we've guided and lose some additional elements to that the burn will go through and we'll get more data points over the next several weeks and months. So that next time, we have this call we can get better information and how the structure will go for the balance of the or Bernie and give some puts and takes.
Yes.
The other piece on that you've got to remember is the FX headwinds that we have forecasted has moved from $15 million $26 million and so if you take that into accounts and we're absorbing that while maintaining guidance between 1.95 on 1.97, so essentially it is raising guidance.
And on revenue and as Eric said, it's still early in the year. We're in unprecedented times with a lot of on knowns out there and so again, we felt it was the right thing to do maintain where we are and see how the remainder of the progress, but what we're seeing is the order book is solid.
And our manufacturing operation units are functioning as as they should inline with our expectations and we weathered some storms in the first quarter, but again, it's I don't think it's appropriate to raise a much higher at this point.
Got it. Thank you got to remember that a piece on the FX.
Great. Thanks for the color.
Thank you.
Thank you and our next question comes from the line up one day no with bank of America.
Hi.
Good morning, Congrats on a quarter and thank you for the growth on your plate in crude as pandemic.
Yes, Thank you Rob really.
I guess my first question is can you just to give oh I'm not a annually on your part participation rate across your different customer segments.
Can you give us such an update for 29 team across biologics generics than pharma and related to this question I know that this along from an opportunity on the call. Good 19 vaccines, but what what participation rate do you anticipate to have.
Call. Good now you're seeing progress in vaccines that are currently in development.
Yes, one is on the on the mission rate last year.
Oh with display our biologics purpose decision rate was higher than it has.
Equal little bit higher.
Hello.
So honored to say get than in the nerd and then we'll pharmaceuticals.
So our vision is.
Yeah.
In regard overnight.
Now back.
Customer, we won't be about possible name.
I can tell you that were on many of the products that we currently well and ball will be going.
Paul hopefully soon that we paid on that I think this is why we have a good very strong.
Depletion rate in vaccines as one of the characteristics is required as for the coating on the Alaska when the Portec technology is the market leading technology.
So we're feeling really good in that regard secondly around that while we start we start thinking about the Italian urgent need to get the barrels manufactured that gives us the ability to flex our global operation.
We are building 40, plus drilling oil near.
The demand of vaccine, while it's important to decide.
Back to the.
The challenge considering we have multiple sites that can produce this products or holding well. That's that's all I would look at it.
On the vaccine perspective.
Part of the space.
Got it.
Thank you.
Backlog of committed orders on proprietary products did increased by 44% year over year 2019. According to your time tell you about you filed.
I was wondering if you could give us an update on your backlog or or proprietary product orders that are committed as of yet, but the first quarter.
What the magnitude of the change hi spend and can you remind us what your average production lead time is from the time, you'll receive an order until your producer and ship it.
Yes, so we will update the quarterly number but I can say is solid.
Since in fact, some of the discussions that we're having in regard to.
Product.
Your next and or vaccine that would.
Make sure that will ensure that that number six that number. Its these solid I think from a from a range of lead times like the teams done a great job to think about where we are today, we monitor is going to vary.
On a weekly basis were about eight to 11, we.
On average it does it is based on the product in the digital capabilities that we provide a around that.
But I would I would say were increased it was eight to 11 weeks at this point of time.
Okay.
Thank you.
Got it.
So taking into account with us on the order patterns from customers is changing flight the customers are actually placing longer orders with us.
So they're not it's not just one or two quarters, it's actually I would over three four quarters maybe beyond.
And so the real positive, but that is and it gives us a lot of greater visibility and being able to meet customer demand.
Within the lead times of the eight to 11 weeks on average.
Okay. Good.
Can you tell us what's embedded in your in your guidance revenue guidance for 2020 as far as the the outlook by customer segment, I mean, biologics generics and pharma what growth revenue growth do you expect.
So one on biologics and we're looking at double digit gold.
On the and will be no low to mid single digits, and then generically mid to high single digit Bill.
Contract manufacturing will be high.
High single digits.
Some of the already double digit growth.
Got it.
Thank you.
But the pricing contribution in the sales revenue growth and the one Q was one and a half percentage points, which is a little bit higher than than your historical average can you talk about the pricing dynamics on on high value products, maybe and your components are and how much pricing you can you can get a given.
Vis vis environment.
Yes, I think when you look at pricing, it's it's plus or minus 1% historically asked after the last three or four years, you're right is that one and a half its little more on the higher end of that so it's a very.
It's not a big variance, but I think what we're seeing right now with we think about the growth there were seen in high value products, particularly to the areas that burning United spoke of.
These tends to be tend to be new molecules. So when we when we bring a customer onto those products.
The price contribution doesn't kick in until a year or two later right so that anniversaries out.
From a new product status. So we're about one and a half of the first quarter.
There will be plus or minus of that going forward.
And I think we're able to maintain our pricing structure would you consider that our focus is the convert more customers to the higher end of high value products.
Okay, Great and my last one if I may I mean, not to nitpick I mean, you're getting good margin expansion greater than five your high value product conversion and the good organic growth on proprietary products, but the gross margin that they're coming in a little bit light relative to my estimate on the contract manufacturer.
Third product segment.
I guess my question is when when could we see mid to high teens gross margin and in that segment.
Relative to high was before 2017 him before.
And.
In in Q1.
We had some costs. So we absorbed within will cross all our operational units and that was in particular impact NCM regarding supporting employees as we go through and Cobot 19, So we have incurred some cost there.
And that was a decision by management.
Right decision to do that if we exclude those costs. Some of his business was normal or margin NCM would it be north of 15% the impact on the proprietary business was a lot less.
But so that gives us.
Encouragement to know that were on the right track and our teams are delivering within contract manufacturing.
To get to the mid to high teens.
We will be making progress throughout 2020 and into early 2021, but we are on the right track.
They were one there was onetime costs.
Okay, Alright sounds good. Thank you very much and I'll follow up offline congratulations.
Thanks, Mike you.
Thank you.
Your next question comes from the line of coordinate olin's with William Blair.
Hi, guys good morning, pointing toward.
Good morning, My first question is around.
Updated kind of top line guidance any.
Answered that little bit earlier or somebody else question, but just wanted to kind of talk more about like on the organic side. So you guys started the year very strong and I think in your prepared remarks, Eric you said that you guys didn't really see any covenant related revenue yet in Q1, so it's probably hard to save from your vantage point, but.
It really I guess can you kind of look at the rest of the year that competence that you have that you guys will be towards the higher end of the organic farmer long term organic guidance on that 60% is that driven by just like the base demand for the business or is it more sell related to that colgan related like incremental demand.
Or kind of if you have to take between that mix, which side doesn't more fall on that you have that confident that you'll get to that 8% as opposed to seven to eight. Thank you guys talked about last quarter.
Yes, Courtney I would say that the confidence is on the base business on the poor business.
We are aware of additional.
Opportunities when it comes to pull that 19 on the solutions are working towards.
But its appfluent dynamic environment in regards to which which therapies.
Therapeutics and or vaccines, we'll get through.
And what time at what time and so what we have better.
His ability and clarity around that that will will bring that into the discussion.
On the cm side, it is a little bit higher.
The Q1 that we definitely this you would.
C.
And I think that will come down a little bit going back to what Bernard said earlier full year pilots now high single digit maybe touching the 10% Mark.
On the proprietary side the underlying core business, we look at Q1.
Q4 of last year and the momentum has been built up on on the core.
It's been relatively consistent so it gives the confidence that guidance that burner walked us through.
Is really is really taking a lot of the opportunity to pull that out.
Hey, it's part of it may want that now there's a lot of silicon over but.
We need to see more into more concrete and that's probably a bit more visibility as we progress through the second quarter here.
And we'll give you it.
At or insight into that I think once into call, but it's still early there's a lot of moving pieces.
And in that area.
Okay got it thanks guys.
Thank you.
Thank you.
I'm showing no further questions at this time, so with that I'll turn the call back over to Quintin Lai life for closing remarks.
Thank you Andrew Thank you for joining us on today's conference call and online archive of the broadcast will be available on our website at west pharma Dot com in the investors section.
Additionally, you may access a replay through Thursday April thirtyth by using the dial in numbers and conference I'd provided at the end of today's earnings release.
That concludes this call today, a stay say stay healthy have a nice day.
Ladies and gentlemen, thank you for participating in todays conference. This does conclude the program and you may all disconnect everyone have a wonderful day.
[music].